Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel速M In BCG Refractory NMIBC
The purpose of this study is to determine whether Nanoxel速M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.
Non Muscle Invasive Bladder Cancer
DRUG: Nanoxel速M|DRUG: Mitomycin-C
Recurrence free rate, Recurrence free rate will be summarized as the percentage of participants who achieved a confirmed recurrence free as assessed by urine cytology and cystoscopy. Recurrence means reappearance of high-risk disease (high grade, T1 or CIS) after the start of therapy., 1 year
Recurrence free rate, Recurrence free rate will be summarized as the percentage of participants who achieved a confirmed recurrence free as assessed by urine cytology and cystoscopy.Recurrence means reappearance of high-risk disease (high grade, T1 or CIS) after the start of therapy., 6 months, 2 years|Overall survival, Time from random assignment to death resulting from any cause., 2 years|Number of participants with adverse events as assessed by CTCAE v4.0, Adverse event (AE) is as any AE occurring or worsening from the first treatment of any study drug to the last dose of the last study drug. Severity grades according to NCI CTCAE version 4.0., 2 years
The purpose of this study is to determine whether Nanoxel速M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.